flutamide has been researched along with Osteoporosis in 9 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Men with prostate cancer who lacked radiographically detectable metastases were treated in a prospective trial of IAD." | 2.77 | Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. ( Chen, S; Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Jiang, PY; Kuo, KF; Pitzel, P; Yu, EY, 2012) |
| "Treatment with pamidronate resulted in a 7." | 2.70 | The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. ( Bryant, C; De Souza, P; Diamond, TH; Kersley, JH; Lynch, WJ; Smith, A; Winters, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spry, NA | 1 |
| Galvão, DA | 1 |
| Davies, R | 1 |
| La Bianca, S | 1 |
| Joseph, D | 1 |
| Davidson, A | 1 |
| Prince, R | 1 |
| O'Rourke, ME | 1 |
| Ruble, K | 1 |
| Yu, EY | 1 |
| Kuo, KF | 1 |
| Gulati, R | 1 |
| Chen, S | 1 |
| Gambol, TE | 1 |
| Hall, SP | 1 |
| Jiang, PY | 1 |
| Pitzel, P | 1 |
| Higano, CS | 1 |
| Preston, DM | 1 |
| Torréns, JI | 1 |
| Harding, P | 1 |
| Howard, RS | 1 |
| Duncan, WE | 1 |
| McLeod, DG | 1 |
| Diamond, TH | 2 |
| Bucci, J | 1 |
| Kersley, JH | 2 |
| Aslan, P | 1 |
| Lynch, WB | 1 |
| Bryant, C | 2 |
| Miki, Y | 1 |
| Suzuki, T | 1 |
| Hatori, M | 1 |
| Igarashi, K | 1 |
| Aisaki, KI | 1 |
| Kanno, J | 1 |
| Nakamura, Y | 1 |
| Uzuki, M | 1 |
| Sawai, T | 1 |
| Sasano, H | 1 |
| Prezelj, J | 1 |
| Kocijancic, A | 1 |
| Winters, J | 1 |
| Smith, A | 1 |
| De Souza, P | 1 |
| Lynch, WJ | 1 |
| Berruti, A | 1 |
| Dogliotti, L | 1 |
| Terrone, C | 1 |
| Cerutti, S | 1 |
| Isaia, G | 1 |
| Tarabuzzi, R | 1 |
| Reimondo, G | 1 |
| Mari, M | 1 |
| Ardissone, P | 1 |
| De Luca, S | 1 |
| Fasolis, G | 1 |
| Fontana, D | 1 |
| Rossetti, SR | 1 |
| Angeli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix[NCT03202381] | Phase 4 | 35 participants (Anticipated) | Interventional | 2017-06-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for flutamide and Osteoporosis
| Article | Year |
|---|---|
Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormon | 2012 |
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Cr | 2001 |
6 other studies available for flutamide and Osteoporosis
| Article | Year |
|---|---|
Addressing bone loss in the cancer survivor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Female; Flutamide; Huma | 2009 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides | 2002 |
Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
Topics: Aged; Alcohol Drinking; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Comorbidity | 2004 |
Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
Topics: Alkaline Phosphatase; Aminoglutethimide; Androstadienes; Aromatase Inhibitors; Base Sequence; Cell L | 2007 |
Comment on spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Topics: Female; Flutamide; Gonadotropin-Releasing Hormone; Humans; Hyperandrogenism; Osteoporosis; Spironola | 1999 |
Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplasti | 2002 |